Processa Pharmaceuticals
PCSA
11 hedge funds and large institutions have $75.9K invested in Processa Pharmaceuticals in 2025 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 4 increasing their positions, 1 reducing their positions, and 2 closing their positions.
300% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 1
100% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 2
22% more funds holding
Funds holding: 9 → 11 (+2)
20% more capital invested
Capital invested by funds: $63.2K → $75.9K (+$12.7K)
0% less ownership
Funds ownership: 0.13% → 0.13% (-0%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$17.2K |
| 2 |
VF
Virtu Financial
New York
|
+$16.4K |
| 3 |
AGM
Alpine Global Management
New York
|
+$14.3K |
| 4 |
CSS
Cubist Systematic Strategies
Stamford,
Connecticut
|
+$11.2K |
| 5 |
Jane Street
New York
|
+$5.14K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$20.7K |
| 2 |
MMA
Miracle Mile Advisors
Los Angeles,
California
|
-$3.7K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
-$7 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
VF
1
Virtu Financial
New York
| $21K | +$16.4K | +2,460 | +142% |
|
|
2
UBS Group
Zurich,
Switzerland
| $13.2K | +$17.2K | +2,582 | +129,100% |
|
|
AGM
3
Alpine Global Management
New York
| $10.9K | +$14.3K | +2,137 | New |
|
4
Geode Capital Management
Boston,
Massachusetts
| $10.4K | +$4.31K | +646 | +47% |
|
|
CSS
5
Cubist Systematic Strategies
Stamford,
Connecticut
| $8.58K | +$11.2K | +1,674 | New |
|
6
Vanguard Group
Malvern,
Pennsylvania
| $5.01K | – | – | – |
|
|
7
Jane Street
New York
| $3.95K | +$5.14K | +771 | New |
|
|
SFA
8
Sequoia Financial Advisors
Akron,
Ohio
| $2.25K | +$2.94K | +440 | New |
|
|
TRCT
9
Tower Research Capital (TRC)
New York
| $505 | -$7 | -1 | -1% |
|
10
Wells Fargo
San Francisco,
California
| $32 | – | – | – |
|
11
Bank of America
Charlotte,
North Carolina
| $22 | +$20 | +3 | +300% |
|
|
SS
12
SBI Securities
Tokyo,
Japan
| $2 | – | – | – |
|
|
AC
13
Armistice Capital
New York
| – | -$20.7K | -2,240 | Closed |
|
|
MMA
14
Miracle Mile Advisors
Los Angeles,
California
| – | -$3.7K | -400 | Closed |
|
PCSA Hedge Fund Activity: Q2 2025 in Review
11 of the 7,604 institutional investors tracked by Wall St. Rank reported a position in Processa Pharmaceuticals (PCSA) for Q2 2025, worth a combined $75.9K — up 20% from $63.2K a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new PCSA positions and 2 closed out — a net gain of 2 holders — while 4 added to existing stakes and 1 trimmed.
The largest buyer was UBS Group, adding an estimated $17.2K. The largest seller was Armistice Capital, exiting entirely with an estimated $20.7K sold.
- 11 institutional investors held Processa Pharmaceuticals (PCSA) as of Q2 2025, up from 9 in Q1 2025.
- Funds reported $75.9K of Processa Pharmaceuticals stock for Q2 2025, up 20% quarter-over-quarter.
- 4 funds opened new Processa Pharmaceuticals positions in Q2 2025 and 2 closed out, a net change of +2 holders.
- The largest Processa Pharmaceuticals buyer in Q2 2025 was UBS Group, an estimated $17.2K added.
- The largest Processa Pharmaceuticals seller in Q2 2025 was Armistice Capital, an estimated $20.7K sold.
Based on aggregated 13F filings for Q2 2025.